Explore 3 Stock Ideas & Industry Insights Download Free Report

CapsoVision, Inc. Common Stock

Company price
6.27 USD -0.10 ( 1.57%)
Last update at 2026-11-11T21:01:00Z
VOLUME
56213
Market Cap
319.30M

Momentum Score

…

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
6.27
Low
6.58
High
52 Week Price Range
4.34
Low
15.37
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CapsoVision develops and commercializes capsule endoscopy systems that capture 360-degree, internally stored images for gastrointestinal diagnostics; it operates in the medical device diagnostics industry. Long-term growth may be driven by broader adoption of non-invasive GI screening, expansion into new clinical indications and geographies, and uptake of its cloud-based image management and service model, which could support recurring revenues. Key investment risks include limited commercial scale and liquidity, intense competition from larger endoscopy players, dependence on reimbursement and regulatory approvals for new indications, and execution risk in sales and manufacturing.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
6.37
Dividend Yield
-
Revenue TTM
13.89M
Revenue Per Share
0.29
Gross Profit TTM
7.07M
Debt / Equity
0.07
ROE
-335.06%
Net Debt
-9.22M
ROCE
-185.75%
Diluted EPS TTM
-1.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Income before tax -25.29M -19.89M -11.29M
Net income -25.32M -19.90M -11.30M
Selling general administrative 6.85M 4.21M 1.97M
Selling and marketing expenses 7.53M 6.97M 5.53M
Gross profit 7.17M 6.38M 5.49M
Reconciled depreciation 0.57M 0.52M 0.39M
Ebit -25.52M -19.92M -11.35M
Ebitda -24.95M -19.40M -10.96M
Depreciation and amortization 0.57M 0.52M 0.39M
Operating income 0.23M -19.92M -11.35M
Other operating expenses 39.07M 31.67M 21.10M
Tax provision 0.02M 0.01M 0.01M
Interest income 0.27M 0.03M 0.05M
Net interest income 0.27M 0.03M 0.05M
Income tax expense 0.02M 0.01M 0.01M
Total revenue 13.55M 11.76M 9.75M
Total operating expenses 32.69M 26.29M 16.84M
Cost of revenue 6.38M 5.38M 4.26M
Total other income expense net -25.52M 0.03M 0.05M
Net income from continuing ops -25.32M -19.90M -11.30M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Total assets 18.16M 16.80M 21.53M
Other current assets 1.07M 0.90M 0.58M
Total liab 4.90M 146.31M 131.37M
Total stockholder equity 13.26M -129.51M -109.84M
Other current liab 2.70M 0.50M 0.69M
Common stock 0.05M 0.00M 0.00M
Capital stock 0.05M 0.00M 0.00M
Retained earnings -155.66M -130.35M -110.45M
Cash 10.11M 9.32M 14.56M
Total current liabilities 4.43M 1.80M 1.51M
Current deferred revenue 0.18M 0.13M 0.10M
Net debt -9.22M -8.08M -13.04M
Short term debt 0.41M 0.35M 0.28M
Short long term debt total 0.89M 1.24M 1.51M
Other stockholder equity 168.88M -78.84M -64.07M
Total current assets 16.67M 14.85M 19.20M
Net receivables 2.50M 2.00M 1.87M
Inventory 2.99M 2.63M 2.19M
Accounts payable 1.14M 0.75M 0.36M
Non currrent assets other 0.04M 0.04M 0.04M
Non current assets total 1.50M 1.96M 2.33M
Capital lease obligations 0.89M 1.24M 1.51M
Breakdown 2025-12-31 2024-12-31 2023-12-31
Type yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31
Investments - -0.15M -0.75M
Total cashflows from investing activities -0.09M -0.15M -0.75M
Net borrowings 0.00M 0.00M -
Total cash from financing activities 23.60M 15.07M 20.53M
Net income -25.32M -19.90M -11.30M
Change in cash 0.79M -5.24M 9.01M
Begin period cash flow 9.32M 14.56M 5.55M
End period cash flow 10.11M 9.32M 14.56M
Total cash from operating activities -22.86M -20.09M -10.80M
Issuance of capital stock 26.56M 15.00M 20.36M
Depreciation 0.57M 0.52M 0.39M
Change to inventory -0.36M -0.43M -0.67M
Change to account receivables -0.48M -0.18M 0.01M
Other cashflows from financing activities -3.18M 15.07M 20.53M
Capital expenditures 0.09M 0.15M 0.75M
Change in working capital 1.19M -0.98M 0.16M
Stock based compensation 0.83M 0.16M 0.04M
Other non cash items -0.13M 0.11M -0.09M
Free cash flow -22.95M -20.24M -11.56M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
CV
CapsoVision, Inc. Common Stock
-0.10
1.57%
6.27 - - 22.99 24.75 22.85
ABT
Abbott Laboratories
-1.17
1.06%
109.29 25.97 17.24 3.57 3.20 3.81
MDT
Medtronic PLC
0.02
0.02%
101.61 26.60 15.87 3.35 2.08 3.90
SYK
Stryker Corporation
-5.50
1.70%
318.79 29.23 16.86 4.18 4.51 4.63
SEMHF
Siemens Healthineers AG
0.30
0.63%
48.57 39.57 21.32 3.01 3.29 2.95

Profile*

CapsoVision, Inc. Common Stock

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.

18805 Cox Avenue, Saratoga, CA, United States, 95070

408 624 1488

99

Name Title Year Born
Mr. Kang-Huai Wang Co-Founder, President, CEO & Director 1958
Mr. Douglas Atkinson Senior Vice President of Global Sales 1969
Mr. David Garcia Compliance Officer, SVP of Finance, Principal Financial & Accounting Officer 1975
Helen Chau Manager of Human Resources NA
Anna Krylova Corporate Controller NA
Mr. Kang-Huai Wang Co-Founder, President, CEO & Director 1957
Mr. Douglas Atkinson Senior Vice President of Global Sales 1968

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…